Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

13.15 EUR

+1.94 %

5,625 following
Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

+1.94 %
-7.39 %
-5.40 %
-2.23 %
-1.50 %
+50.46 %
+222.30 %
+71.73 %
-97.83 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
94.86M EUR
Turnover
68.88K EUR
P/E (adj.) (25e)
75.23
EV/EBIT (adj.) (25e)
68.32
P/B (25e)
18.7
EV/S (25e)
8.05
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
12.00 EUR
Updated
04.01.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 05.01.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.2
2026

Annual report '25

30.3
2026

General meeting '26

14.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
linkedin.com #terveystalo #tärkeinmielessä #masennus #neuropaattinenkipu #neuromodulaatio... Mielenkiintoinen ja vaikuttava työpäivä tänään #terveystalo Ruoholahden yksikössä, jossa aloitimme joulukuussa magneettistimulaatiohoidot masennus- ja kipupotilaille. Kuvassa neuronavigoiva...
1/20/2026, 4:36 PM
by Kyhnykeisari
45
At Trinity College Dublin, a top university, there is at least an investment in TMS-EMG and EEG research for the early detection of ALS; new research areas are certainly gaining traction regarding the central nervous system and degenerative diseases. I haven’t personally come across...
1/21/2026, 10:15 AM
by Märkäkoira
19
These Simplywall AI estimates have already been discussed before, but they must be getting their evaluations from somewhere. Now Nexstim was in this kind of company on their site – Top 10 Undervalued Stocks Based On Cash Flows In Europe simplywall.st 3 European Stocks That May Be...
1/21/2026, 12:27 PM
by Jatast
18
In addition to the buying rush, one can consider Nexstim’s device in general. For example, if it is the only device on the diagnostic side capable of mapping the necessary information before surgery, would the device not be acquired if an additional xx percent in tariffs is added...
1/19/2026, 1:18 PM
by Jatast
15
Sinaptica at the MedTech World StartUp “village”. Hopefully, money will come pouring in, so we can get the research across the finish line quickly.
yesterday
by Jatast
13
This guy likely won’t stay sitting on his hands in the current political situation, so we’ll just have to wait for the buy orders. Who knows, there might be a rush to buy Nexstim’s devices in the spring before the threatened 25% tariff takes effect, as the customer will ultimately...
1/19/2026, 10:00 AM
9
The price for that combination device hasn’t been announced anywhere, but I would assume that the combination device is somewhat more expensive than just diagnostics. I believe that €350k is even a fairly conservative estimate, considering that diagnostics + therapy would cost around...
1/18/2026, 10:35 AM
by Kyhnykeisari
8
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.